X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.fiercepharma.com/pharma/uk-appeals-court-win-gsk-hook-extra-royalties-astrazeneca-parp-inhibitor-zejula
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/
https://www.onclive.com/view/niraparib-maintenance-extends-pfs-in-newly-diagnosed-ovarian-cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration?utm_medium=email&utm_source=govdelivery#:~:text=On%20August%2011%2C%202023%2C%20the,as%20determined%20by%20an%20FDA%2D
https://endpts.com/janssen-gets-priority-review-for-prostate-cancer-combo-immunogen-reports-q1-elahere-sales/
https://www.fiercepharma.com/pharma/gsk-lurking-metastatic-disease-breast-cancer-patients-spells-trouble-zejula-trial
https://www.reuters.com/business/healthcare-pharmaceuticals/uk-court-orders-gsk-pay-astrazeneca-royalties-total-sales-zejula-2023-04-05/
https://www.globenewswire.com/news-release/2023/02/16/2609811/0/en/Janssen-Presents-Updated-Data-Demonstrating-Improved-Outcomes-from-the-Use-of-Niraparib-in-Combination-with-Abiraterone-Acetate-Plus-Prednisone-as-a-First-Line-Therapy-in-Patients-.html
https://endpts.com/gsk-pulls-another-cancer-indication-for-zejula-at-fdas-request/
https://www.globenewswire.com/news-release/2022/09/12/2513912/0/en/AnaptysBio-Announces-Sale-of-Zejula-Royalties-for-Up-To-45-Million.html
https://www.clinicaltrialsarena.com/news/gsk-zejula-ovarian-cancer-trial/
https://www.gsk.com/en-gb/media/press-releases/zejula-niraparib-shows-durable-and-sustained-long-term-progression-free-survival-benefit-in-the-prima-study-of-first-line-platinum-responsive-advanced-ovarian-cancer/
https://www.biospectrumasia.com/news/26/20600/singapore-approves-gsks-new-cancer-therapy-for-ovarian-cancer.html
https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-present-new-prime-subgroup-analysis-niraparib-ovarian
http://www.pharmafile.com/news/608486/nice-recommends-gsk-s-zejula-niraparib-ovarian-cancer-patients
https://www.globenewswire.com/news-release/2021/12/03/2345756/0/en/Zai-Lab-Announces-Inclusion-of-ZEJULA-Niraparib-in-China-s-National-Reimbursement-Drug-List-for-First-Line-Ovarian-Cancer.html
https://www.ivybraintumorcenter.org/about/newsroom/news/ivy-brain-tumor-center-collaborates-with-gsk-on-new-phase-0-clinical-trial-to-evaluate-niraparib-in-patients-with-brain-cancer/
https://www.clinicaltrialsarena.com/analysis/gsk-cancer-regulatory-roundup/
https://www.fiercepharma.com/pharma/astrazeneca-takes-parp-battle-to-court-suing-for-more-zejula-shares-key-gsk-s-oncology-pivot
https://www.fiercepharma.com/pharma/astrazeneca-takes-parp-battle-to-court-suing-for-more-zejula-shares-key-gsk-s-oncology-pivot
https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-scientific-research-in-ovarian-and-endometrial-cancer-at-sgo-2021-annual-meeting-on-women-s-cancer/
https://www.globenewswire.com/news-release/2020/12/29/2151031/0/en/Zai-Lab-Announces-Inclusion-of-ZEJULA-Niraparib-in-China-s-National-Reimbursement-Drug-List.html#:~:text=28%2C%202020%20(GLOBE%20NEWSWIRE),Healthcare%20Security%20Administration%20(NHSA).
https://www.globenewswire.com/news-release/2020/12/29/2151031/0/en/Zai-Lab-Announces-Inclusion-of-ZEJULA-Niraparib-in-China-s-National-Reimbursement-Drug-List.html#:~:text=28%2C%202020%20(GLOBE%20NEWSWIRE),Healthcare%20Security%20Administration%20(NHSA).
https://www.europeanpharmaceuticalreview.com/news/132185/ec-approves-zejula-niraparib-as-a-monotherapy-for-advanced-ovarian-cancer/
https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-in-advanced-ovarian-cancer/
http://www.pharmafile.com/news/562814/eu-approves-zejula-first-line-monotherapy-maintenance-treatment-advanced-ovarian-cancer
https://endpts.com/with-fda-decision-looming-gsk-sweetens-the-pd-1-pot-for-discovery-partner-anaptysbio-as-hal-barron-doubles-down-on-his-oncology-strategy/
https://www.newswire.ca/news-releases/zejula-is-approved-in-canada-for-first-line-maintenance-treatment-of-women-with-advanced-ovarian-cancer-849289412.html
https://www.globenewswire.com/news-release/2020/09/19/2096146/0/en/Phase-3-NORA-data-of-ZEJULA-niraparib-demonstrate-significant-PFS-benefit-regardless-of-biomarker-status-with-an-improved-safety-profile-when-given-with-individualized-starting-dos.html
https://www.b3cnewswire.com/202008252108/byondis-initiates-phase-i-study-of-adc-vic-trastuzumab-duocarmazine-niraparib-in-her2-expressing-solid-tumors.html
https://www.fiercebiotech.com/biotech/glaxosmithkline-pens-120m-upfront-synthetic-lethality-cancer-pact-fierce-15-winner-ideaya
https://www.globenewswire.com/news-release/2020/05/28/2040124/0/en/Zai-Lab-Announces-Positive-Topline-Results-from-the-NORA-Phase-3-Study-of-ZEJULA-as-Maintenance-Therapy-for-Chinese-Patients-with-Platinum-sensitive-Recurrent-Ovarian-Cancer.html
https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-scientific-innovation-and-advances-in-its-growing-oncology-portfolio-at-asco-2020/
https://www.fiercepharma.com/pharma/asco-az-merck-s-lynparza-levels-up-ovarian-cancer-extending-lives-by-13-months
https://news.cision.com/astrazeneca/r/lynparza-gets-broader-us-ovarian-cancer-approval,c3108407
https://www.fiercepharma.com/pharma/astrazeneca-merck-s-lynparza-wins-bid-to-challenge-gsk-s-zejula-wider-ovarian-cancer-pool
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
https://www.fiercepharma.com/pharma/glaxosmithkline-s-zejula-jumps-ahead-lynparza-all-comers-ovarian-cancer-nod
https://www.prnewswire.com/news-releases/fda-approves-zejula-niraparib-as-the-only-once-daily-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status-301049691.html
https://www.globenewswire.com/fr/news-release/2020/03/16/2000960/0/en/Zai-Lab-Announces-Acceptance-of-sNDA-Submission-of-ZEJULA-Niraparib-for-First-Line-Maintenance-Treatment-of-Ovarian-Cancer-in-China-by-the-NMPA.html
https://www.prnewswire.com/news-releases/us-fda-accepts-gsks-snda-application-for-zejula-niraparib-for-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-301009413.html
https://www.fiercepharma.com/pharma/oncology-rare-diseases-told-story-big-pharma-strategy-2019-will-2020-be-same
https://www.fiercepharma.com/marketing/gsk-rains-astrazeneca-s-parp-parade-expanded-zejula-ovarian-cancer-nod
Market Place
Share 
